CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) - - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA ® (MY-PLY-FAH) (arimoclomol) and one on OLPRUVA ® (sodium phenylbutyrate) are being presented at the 42 nd Annual Meeting of the Southeastern Regional Genetics Group... Read More